Scilex Holding Co

Scilex Holding Company, the specialty pharmaceutical firm that emerged from its de-SPAC business combination with Vickers Vantage Corp. I (Nasdaq: VCKA), filed an 8-K current report with the SEC on December 1, 2025, under accession number 0001193125-25-303037. Vickers Vantage Corp. I completed its initial public offering in 2021 under the sponsorship of Vickers Capital Group, targeting the healthcare and life sciences sector. Following the closing of its business combination in late 2022, Scilex has operated as a public specialty pharmaceutical company focused on non-opioid pain management therapeutics. Sign up for SpacDesk to access full filing history, sponsor profiles, and deal analytics for Scilex and hundreds of other SPAC-origin companies.